Single agent chemotherapy

Phase 1

Single agent chemotherapy is one of 5 therapeutic programs targeting Small Cell Lung Carcinoma (SCLC). It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Small Cell Lung Carcinoma (SCLC)Active, not recruiting

Small Cell Lung Carcinoma (SCLC)Phase 1

Active, not recruiting

Competition

Competitive Landscape

5 competitors in Small Cell Lung Carcinoma (SCLC)

#DrugCompanyPhaseTrials

Tecentriq

Roche

Phase 1

1 2

Hycamtin

MMeitheal

Phase 1

1 3

Paraplatin

AAvyxa

Phase 1

1 4

Vepesid

AAvyxa

Phase 1

1 5

Single agent chemotherapy

Boehringer Ingelheim

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Active, not recruiting

Small Cell Lung Carcinoma (SCLC)

NCT05990738

Clinical

Trials by Indication[1]

Small Cell Lung Carcinoma (SCLC)1 trial

DAREON™-9: A Phase Ib Open-label Dose Escalation and Dose Confirmation Safety Study of Intravenous BI 764532 in Combination With a Single Agent Chemotherapy for the Treatment of Patients With Relapsed/Refractory Small Cell Lung Cancer After Platinum-based Chemotherapy

Active, not recruiting· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT05990738·69 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Single agent chemotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Single agent chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Boehringer Ingelheim company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: Boehringer Ingelheim

Single agent chemotherapy

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Small Cell Lung Carcinoma (SCLC)1 trial

References

Drug Info

Quick Facts

Related News